These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 25463412)

  • 41. Role of Response-to-Diuretic in Predicting Prognosis in Discharged Heart Failure Patients After an Acute Decompensation.
    Feola M; Testa M; Ferreri C; Cardone M; Sola M; Ariotti S; Rosso GL
    Arch Med Res; 2018 Apr; 49(3):198-204. PubMed ID: 30119980
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Galectin-3 is associated with severe heart failure and death: A hospital-based study in Chinese patients.
    Wang N; Dang M; Zhang W; Lei Y; Liu Z
    Scand J Immunol; 2020 May; 91(5):e12826. PubMed ID: 31514240
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comprehensive review of the prognostic value of galectin-3 in heart failure.
    Coburn E; Frishman W
    Cardiol Rev; 2014; 22(4):171-5. PubMed ID: 24407048
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of the Incremental Prognostic Utility of Increasingly Complex Testing in Chronic Heart Failure.
    Ahmad T; O'Brien EC; Schulte PJ; Stevens SR; Fiuzat M; Kitzman DW; Adams KF; Kraus WE; Piña IL; Donahue MP; Zannad F; Whellan DJ; O'Connor CM; Felker GM
    Circ Heart Fail; 2015 Jul; 8(4):709-16. PubMed ID: 26034004
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association of the biomarkers soluble ST2, galectin-3 and growth-differentiation factor-15 with heart failure and other non-cardiac diseases.
    Mueller T; Leitner I; Egger M; Haltmayer M; Dieplinger B
    Clin Chim Acta; 2015 May; 445():155-60. PubMed ID: 25850080
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Limited Added Value of Circulating Inflammatory Biomarkers in Chronic Heart Failure.
    Nymo SH; Aukrust P; Kjekshus J; McMurray JJ; Cleland JG; Wikstrand J; Muntendam P; Wienhues-Thelen U; Latini R; Askevold ET; Gravning J; Dahl CP; Broch K; Yndestad A; Gullestad L; Ueland T;
    JACC Heart Fail; 2017 Apr; 5(4):256-264. PubMed ID: 28359413
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Renal function largely influences Galectin-3 prognostic value in heart failure.
    Zamora E; Lupón J; de Antonio M; Galán A; Domingo M; Urrutia A; Troya M; Bayes-Genis A
    Int J Cardiol; 2014 Nov; 177(1):171-7. PubMed ID: 25499371
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Osteopontin and galectin-3 predict the risk of ventricular tachycardia and fibrillation in heart failure patients with implantable defibrillators.
    Francia P; Adduci C; Semprini L; Borro M; Ricotta A; Sensini I; Santini D; Caprinozzi M; Balla C; Simmaco M; Volpe M
    J Cardiovasc Electrophysiol; 2014 Jun; 25(6):609-16. PubMed ID: 24400815
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Research on clinical value of galectin-3 in evaluating the prognosis of acute heart failure.
    Zhang T; Shao B; Liu GA
    Eur Rev Med Pharmacol Sci; 2017 Oct; 21(19):4406-4410. PubMed ID: 29077153
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Elevated serum uric acid concentration at discharge confers additive prognostic value in elderly patients with acute heart failure.
    Coiro S; Carluccio E; Biagioli P; Alunni G; Murrone A; D'Antonio A; Zuchi C; Mengoni A; Girerd N; Borghi C; Ambrosio G
    Nutr Metab Cardiovasc Dis; 2018 Apr; 28(4):361-368. PubMed ID: 29501446
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22.
    Grandin EW; Jarolim P; Murphy SA; Ritterova L; Cannon CP; Braunwald E; Morrow DA
    Clin Chem; 2012 Jan; 58(1):267-73. PubMed ID: 22110019
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The fibrosis marker galectin-3 and outcome in the general population.
    de Boer RA; van Veldhuisen DJ; Gansevoort RT; Muller Kobold AC; van Gilst WH; Hillege HL; Bakker SJ; van der Harst P
    J Intern Med; 2012 Jul; 272(1):55-64. PubMed ID: 22026577
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Galectin-3 and Arterial Stiffness in Patients with Heart Failure: A Pilot Study.
    Oikonomou E; Karlis D; Tsalamadris S; Siasos G; Chrysohoou C; Vogiatzi G; Dimitropoulos S; Charalambous G; Kouskouni E; Tousoulis D
    Curr Vasc Pharmacol; 2019; 17(4):396-400. PubMed ID: 29968538
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic value of galectin-3 in adults with congenital heart disease.
    Baggen VJM; van den Bosch AE; Eindhoven JA; Menting ME; Witsenburg M; Cuypers JAAE; Boersma E; Roos-Hesselink JW
    Heart; 2018 Mar; 104(5):394-400. PubMed ID: 28942393
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prospective Validation of a Screening Biomarker Approach Combining Amino-Terminal Pro-Brain Natriuretic Peptide With Galectin-3 Predicts Death and Cardiovascular Events in Asymptomatic Hemodialysis Patients.
    Voroneanu L; Siriopol D; Apetrii M; Hogas S; Onofriescu M; Nistor I; Kanbay M; Dumea R; Cusai S; Cianga P; Constantinescu D; Covic A
    Angiology; 2018 May; 69(5):449-455. PubMed ID: 28974104
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: An Individual Patient Data Meta-Analysis.
    Aimo A; Januzzi JL; Vergaro G; Ripoli A; Latini R; Masson S; Magnoli M; Anand IS; Cohn JN; Tavazzi L; Tognoni G; Gravning J; Ueland T; Nymo SH; Brunner-La Rocca HP; Bayes-Genis A; Lupón J; de Boer RA; Yoshihisa A; Takeishi Y; Egstrup M; Gustafsson I; Gaggin HK; Eggers KM; Huber K; Tentzeris I; Tang WHW; Grodin J; Passino C; Emdin M
    Circulation; 2018 Jan; 137(3):286-297. PubMed ID: 29335288
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial.
    Lopez-Andrès N; Rossignol P; Iraqi W; Fay R; Nuée J; Ghio S; Cleland JG; Zannad F; Lacolley P
    Eur J Heart Fail; 2012 Jan; 14(1):74-81. PubMed ID: 22089058
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serum Galectin-3 levels and all-cause and cardiovascular mortality in maintenance hemodialysis patients: a prospective cohort study.
    Liu S; Wu Q; Zhang S; Wang Z; Liu H; Teng L; Xiao P; Lu Y; Wang X; Dong C; Xiao J; Zhang J
    BMC Nephrol; 2022 Jan; 23(1):5. PubMed ID: 34979958
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dynamics and prognostic role of galectin-3 in patients with advanced heart failure, during left ventricular assist device support and following heart transplantation.
    Coromilas E; Que-Xu EC; Moore D; Kato TS; Wu C; Ji R; Givens R; Jorde UP; Takayama H; Naka Y; George I; Mancini D; Schulze PC
    BMC Cardiovasc Disord; 2016 Jun; 16():138. PubMed ID: 27301475
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The GALA study: relationship between galectin-3 serum levels and short- and long-term outcomes of patients with acute heart failure.
    Miró Ò; González de la Presa B; Herrero-Puente P; Fernández Bonifacio R; Möckel M; Mueller C; Casals G; Sandalinas S; Llorens P; Martín-Sánchez FJ; Jacob J; Bedini JL; Gil V
    Biomarkers; 2017 Dec; 22(8):731-739. PubMed ID: 28406038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.